Anest. intenziv. Med. 2005;16(1):31-34

Možnosti imunomodulace zánětlivé odpovědi u kriticky nemocných - novinky z let 2003 a 2004Intensive Care Medicine

V. Šrámek
Anesteziologicko-resuscitační klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně

Imunomodulace zánětlivé odpovědi je velice široké téma. V tomto přehledu se soustředím na léčebné intervence, které ovlivňují funkci imunitního systému v užším slova smyslu (vrozená buněční imunita, získaná buněčná a humorální imunita). Nebudu rozebírat související témata, např. ovlivnění sekundárních efektorů zánětlivé odpovědi (oxid dusnatý, metabolity kyseliny arachidonové) či ovlivnění oxidačního stresu.

Published: February 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šrámek V. Možnosti imunomodulace zánětlivé odpovědi u kriticky nemocných - novinky z let 2003 a 2004. Anest. intenziv. Med. 2005;16(1):31-34.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nierhaus, A., Montag, B., Frings, D. et al. Initial decrease and sustained depresson of HLA-DR expression on monocytes is predictive of outcome in SIRS and sepsis. Anaesthesiology, 93, 2000, A 461. Go to original source...
    2. Allen, M. L., Peters, M. J., Goldman, A. et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit. Care Med., 2002, 30, 5, p. 1140-1145. Go to original source... Go to PubMed...
    3. Průcha, M., Herold, I., Zazula, R. et al. Monocytární deaktivace a produkce TNFalfa ex vivo - prognostické parametry u pacientů jednotek intenzivní péče. Anest. intenziv. Med., 2003, 14, s. 223-227.
    4. Monneret, G., Debard, A. L., Venet, F. et al. Marked elevation of human circulating regulatory T cells in sepsis-induced immunoparalysis. Crit. Care Med., 2003, 31, 7, p. 2068-2071. Go to original source... Go to PubMed...
    5. Brunner, M., Krenn, C., Roth, G. et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med., 2004, 30, 7, p. 1468-1473. Go to original source... Go to PubMed...
    6. Monneret, G., Finck, M. E., Venet, F. et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol. Lett., 2004, 15, 2, p. 193-198. Go to original source... Go to PubMed...
    7. Fumeaux, T., Dufour, J., Stern, S. et al. Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines. Intensive Care Med., 2004 [Epub ahead of print]. Go to original source... Go to PubMed...
    8. Roth, G., Moser, B., Krenn, C., Brunner, M. et al. Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. Biochem. Biophys. Res. Commun., 2003, 308, 4, p. 840-846. Go to original source... Go to PubMed...
    9. Le Tulzo, Y., Pangault, C., Gacouin, A. et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock, 2002, 6, p. 487-494. Go to original source... Go to PubMed...
    10. Tamandl, D., Bahrami, M., Wessner, B. et. al. Modulation of toll-like receptor 4 expression on human monocytes by tumor necrosis factor and interleukin-6: tumor necrosis factor evokes lipopolysaccharide hyporesponsiveness, whereas interleukin-6 enhances lipopolysaccharide activity. Shock, 2003, 20, 3, p. 224-229. Go to original source... Go to PubMed...
    11. Derhaschnig, U., Bergmair, D., Marsik, C. et al. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit. Care Med., 2004, 32, 5, p. 1136-1340. Go to original source... Go to PubMed...
    12. Kinasewitz, G. T., Yan, S. B., Basson, B. et al. For the PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit. Care, 2004, 8, 2, R82-90. Go to original source... Go to PubMed...
    13. Alkharfy, K. M., Kellum, J. A., Matzke, G. R. Unintended immunomodulation: part I. Effects of common clinical conditions on cytokine biosynthesis. Shock, 2000, 13, 5, p. 333-345. Go to original source... Go to PubMed...
    14. Alkharfy, K. M., Kellum, J. A., Matzke, G. R. Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock, 2000, 13, 5, p. 346-360. Go to original source... Go to PubMed...
    15. Gogos, C. A., Skoutelis, A., Lekkou, A. et al. Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother., 2004, 48, 8, p. 2793-2798. Go to original source... Go to PubMed...
    16. Uusaro, A., Russell, J. A. Could anti-inflammatory actions of catecholamines explain the possible beneficial effects of supranormal oxygen delivery in critically ill surgical patients? Intensive Care Med., 2000, 26, 3, p. 299-304. Go to original source... Go to PubMed...
    17. Schnuelle, P., Berger, S., de Boer, J. et al. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation, 2001, 72, 3, p. 455-463. Go to original source... Go to PubMed...
    18. Bergmann, M., Gornikiewicz, A., Tamandl, D. et al. Continuous therapeutic epinephrine but not norepinephrine prolongs splanchnic IL-6 production in porcine endotoxic shock. Shock, 2003, 20, 6, p. 575-581. Go to original source... Go to PubMed...
    19. van den Berghe, G., Wouters, P., Weekers, F. et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med., 2001, 345, 19, p. 1359-1367. Go to original source... Go to PubMed...
    20. Weekers, F., Giulietti, A. P., Michalaki, M. et al. Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology, 2003, 144, 12, p. 5329-5338. Go to original source... Go to PubMed...
    21. Krogh-Madsen, R., Moller, K. et al. Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. Am. J. Physiol. Endocrinol. Metab., 2004, 286, 5, E766-772. Go to original source... Go to PubMed...
    22. Marik, P. E., Raghavan, M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med., 2004, 30, p. 748-756. Go to original source... Go to PubMed...
    23. Ronco, C., Tetta, C., Mariano, F. et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif. Organs., 2003, 27, 9, p. 792-801. Go to original source... Go to PubMed...
    24. Joannes-Boyau, O., Rapaport, S., Bazin, R. et al. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J., 2004, 50, 1, p. 102-109. Go to original source... Go to PubMed...
    25. Morgera, S., Slowinski, T., Melzer, C. et al. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am. J. Kidney Dis., 2004, 43, 3, p. 444-453. Go to original source... Go to PubMed...
    26. Sato, T., Shoji, H., Koga, N. Endotoxin adsorption by polymyxin B immobilized fiber column in patients with systemic inflammatory response syndrome: the Japanese experience. Ther. Apher. Dial., 2003, 7, 2, p. 252-258. Go to original source... Go to PubMed...
    27. Ono, S., Tsujimoto, H., Matsumoto, A. et al. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am. J. Surg., 2004, 188, 2, p. 150-156. Go to original source... Go to PubMed...
    28. Lonnemann, G., Novick, D., Rubinstein, M. et al. A switch to high-flux helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis. Blood Purif., 2003, 21, 3, p. 225-231. Go to original source... Go to PubMed...
    29. Yekebas, E. F., Eisenberger, C. F., Ohnesorge, H. et al. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit. Care Med., 2001, 29, 7, p. 1423-1430. Go to original source... Go to PubMed...
    30. Montejo, J. C., Zarazaga, A., Lopez-Martinez, J. et al. Spanish Society of Intensive Care Medicine and Coronary Units. Immunonutrition in the intensive care unit. A systematic review and consensus statement. Clin. Nutr., 2003, 22, 3, p. 221-233. Go to original source... Go to PubMed...
    31. Bertolini, G., Iapichino, G., Radrizzani, D. et al. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med., 2003, 29, 5, p. 834-840. Go to original source... Go to PubMed...
    32. Stechmiller, J. K., Childress, B., Porter, T. Arginine immunonutrition in critically ill patients: a clinical dilemma. Am. J. Crit. Care, 2004, 13, 1, p. 17-23. Go to original source...
    33. Chiolero, R. L., Berger, M. M. Improving nutritional support in critically Ill septic patients: glutamine alone or in combination? Nutrition, 2002, 18, 9, p. 723-724. Go to original source... Go to PubMed...
    34. Flaring, U. B., Rooyackers, O. E., Wernerman, J. et al. Glutamine attenuates post-traumatic glutathione depletion in human muscle. Clin. Sci. (Lond)., 2003, 104, 3, p. 275-282. Go to original source... Go to PubMed...
    35. Exner, R., Tamandl, D., Goetzinger, P. et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Ann. Surg., 2003, 237, 1, p. 110-115. Go to original source... Go to PubMed...
    36. Poindexter, B. B., Ehrenkranz, R. A., Stoll, B. J. et al. National Institute of Child Health and Human Development Neonatal Research Network. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics, 2004, 113, 5, p. 1209-1215. Go to original source... Go to PubMed...
    37. Boelens, P. G., Houdijk, A. P., Fonk, J. C. et al. Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. J. Nutr., 2002, 132, 9, p. 2580-2586. Go to original source... Go to PubMed...
    38. Hall, J. C., Dobb, G., Hall, J., de Sousa, R., Brennan, L., McCauley, R. A prospective randomized trial of enteral glutamine in critical illness. Intensive Care Med., 2003, 29, 10, p. 1710-1716. Go to original source... Go to PubMed...
    39. Mayer, K., Fegbeutel, C., Hattar, K. et al. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med., 2003, 29, 9, p. 1472-1481. Go to original source... Go to PubMed...
    40. Mayer, K., Gokorsch, S., Fegbeutel, C. et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am. J. Respir. Crit. Care Med., 2003, 167, 10, p. 1321-1328. Go to original source... Go to PubMed...
    41. Harbarth, S., Garbino, J., Pittet, D. et al. Is anti-tumor necrosis factor therapy associated with increased mortality in patients with severe sepsis caused by pneumonia? J. Infect. Dis., 2004, 189, 9, p. 1743. Go to original source... Go to PubMed...
    42. Oberbeck, R. Therapeutic implications of immune-endocrine interactions in the critically ill patients. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2004, 2, p. 129-139. Go to original source... Go to PubMed...
    43. Uronen-Hansson, H., Allen, M. L. et al. Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood. Growth. Horm. IGF Res., 2003, 13, 5, p. 282-286. Go to original source... Go to PubMed...
    44. Marx, C., Petros, S., Bornstein, S. R. el al. Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and cortisol. Crit. Care Med., 2003, 31, 5, p. 1382-1388. Go to original source... Go to PubMed...
    45. Dhatariya, K. K. Is there a role for dehydroepiandrosterone replacement in the intensive care population? Intensive Care Med., 2003, 29, 11, p. 1877-1880. Go to original source... Go to PubMed...
    46. Dunser, M. W., Hasibeder, W. R., Wenzel, V. et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit. Care Med., 2004. 32, 6, p. 1266-1271. Go to original source... Go to PubMed...
    47. Annane, D., Bellissant, E., Bollaert, P. et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev., 2004, 1, CD002243. Go to original source... Go to PubMed...
    48. Keh, D., Boehnke, T., Weber-Cartens, S. et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med., 2003, 167, 4, p. 512-520. Go to original source... Go to PubMed...
    49. Le Tulzo, Y., Pangault, C., Amiot, L. et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am. J. Respir. Crit. Care Med., 2004, 169, 10, p. 1144-1151. Go to original source... Go to PubMed...
    50. Ohlsson, A., Lacy, J. B. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev., 2004, 1, :CD000361. Go to original source... Go to PubMed...
    51. Friedrich, I., Silber, R. E., Baumann, B. et al. IgM-enriched immunoglobulin preparation for immunoprophylaxis in cardiac surgery. Eur. J. Med. Res., 2002, 7, 12, p. 544-549.
    52. Darenberg, J., Ihendyane, N., Sjolin, J. et al. Strept Ig Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis., 2003, 37, 3, p. 333-340. Go to original source... Go to PubMed...
    53. Nierhaus, A., Montag, B., Timmler, N. et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med., 2003, 4, p. 646-651. Go to original source... Go to PubMed...
    54. Schneider, C., von Aulock, S., Zedler, S. et al. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann. Surg., 2004, 239, 1, p. 75-81. Go to original source... Go to PubMed...
    55. Root, R. K., Lodato, R. F., Patrick, W. et al. Pneumonia Sepsis Study Group. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med., 2003, 2, p. 367-373. Go to original source... Go to PubMed...
    56. Schaefer, H., Engert, A., Grass, G. et al. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. Ann. Surg., 2004, 240, 1, p. 68-75. Go to original source... Go to PubMed...
    57. Spuck, S., Schaaf, B., Wiedorn, K. H. et al. G-CSF application in patients with severe bacterial pneumonia increases IL-10 expression in neutrophils. Respir. Med., 2003, 97, 1, p. 51-58. Go to original source... Go to PubMed...
    58. Weiss, M., Voglic, S., Harms-Schirra, B. et al. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med., 2003, 29, 6, p. 904-914. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.